Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis.

Literature DB >> 1417051

The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis.

M M Brett¹, E J Simmonds, A T Ghoneim, J M Littlewood.

Abstract

We report the results of a clinical trial. Patients enrolled had serum IgG titres against Pseudomonas aeruginosa above the control range. Assignment to the observation or treatment group was by minimisation. Significant signs or symptoms in any patient prompted antipseudomonal treatment. In addition, the treatment group received antipseudomonal treatment at intervals of four months until the serum IgG titre returned to the control range. P aeruginosa was isolated intermittently from patients in the main trial. Nineteen patients were enrolled (12 observation, seven treatment). After one year in the trial changes in parameters studied, including forced expiratory volume in one second, IgG titre, serum IgG concentrations, and frequency of P aeruginosa isolation had improved in the treated group and worsened in the observation group.

Entities: Disease Species

Mesh：

Substances：

Year: 1992 PMID： 1417051 PMCID： PMC1793633 DOI： 10.1136/adc.67.9.1086

Source DB: PubMed Journal: Arch Dis Child ISSN： 0003-9888 Impact factor: 3.791

11 in total

1. Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors: H SHWACHMAN; L L KULCZYCKI
Journal: AMA J Dis Child Date: 1958-07

2. The systematic evaluation of the chest radiograph in cystic fibrosis.

Authors: A R Chrispin; A P Norman
Journal: Pediatr Radiol Date: 1974

3. Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis.

Authors: M M Brett; A T Ghoneim; J M Littlewood
Journal: Arch Dis Child Date: 1986-11 Impact factor: 3.791

4. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.

Authors: S J Pocock; R Simon
Journal: Biometrics Date: 1975-03 Impact factor: 2.571

5. Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin.

Authors: S P Conway; M G Miller; C Ramsden; J M Littlewood
Journal: Acta Paediatr Scand Date: 1985-01

6. Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis.

Authors: T Jensen; S S Pedersen; N Høiby; C Koch
Journal: Eur J Clin Microbiol Date: 1987-12 Impact factor: 3.267

7. Serum IgG antibodies in patients with cystic fibrosis with early Pseudomonas aeruginosa infection.

Authors: M M Brett; A T Ghoneim; J M Littlewood
Journal: Arch Dis Child Date: 1987-04 Impact factor: 3.791

8. Pseudomonas aeruginosa antibodies in blood spots from patients with cystic fibrosis.

Authors: V Thanasekaraan; M S Wiseman; R J Rayner; E J Hiller; D J Shale
Journal: Arch Dis Child Date: 1989-11 Impact factor: 3.791

9. Prediction and diagnosis of early Pseudomonas aeruginosa infection in cystic fibrosis: a follow-up study.

Authors: M M Brett; A T Ghoneim; J M Littlewood
Journal: J Clin Microbiol Date: 1988-08 Impact factor: 5.948

10. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis.

Authors: M E Hodson; C M Roberts; R J Butland; M J Smith; J C Batten
Journal: Lancet Date: 1987-01-31 Impact factor: 79.321

13 in total

The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis.

1. Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

2. The systematic evaluation of the chest radiograph in cystic fibrosis.

3. Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis.

4. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.

5. Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin.

6. Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis.

7. Serum IgG antibodies in patients with cystic fibrosis with early Pseudomonas aeruginosa infection.

8. Pseudomonas aeruginosa antibodies in blood spots from patients with cystic fibrosis.

9. Prediction and diagnosis of early Pseudomonas aeruginosa infection in cystic fibrosis: a follow-up study.

10. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis.

1. Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis.

2. Serum IgG titres against Pseudomonas aeruginosa.

Review 3. Aerosol antibiotic treatment in cystic fibrosis.

4. Anti-Pseudomonas aeruginosa antibody detection in patients with bronchiectasis without cystic fibrosis.

Review 5. Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis.

6. Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis.

7. Specific decrease of anti-pseudomonal IgA after anti-pseudomonal therapy in cystic fibrosis.

Review 8. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

9. Genotype-phenotype correlation in cystic fibrosis patients bearing [H939R;H949L] allele.

Review 10. Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.